+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Premature Ejaculation Treatment - Global Strategic Business Report

  • PDF Icon

    Report

  • 189 Pages
  • December 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309807
The global market for Premature Ejaculation Treatment was estimated at US$2.7 Billion in 2023 and is projected to reach US$4.4 Billion by 2030, growing at a CAGR of 7.4% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Premature Ejaculation Treatment: Addressing a Common Condition

Premature ejaculation (PE) is a common sexual disorder in men, characterized by ejaculation that occurs sooner than desired during sexual activity, often within a minute of penetration. This condition can lead to distress, anxiety, and relationship difficulties, significantly impacting a man's quality of life. Premature ejaculation is typically classified into two types: lifelong (primary), where the condition has been present since the onset of sexual activity, and acquired (secondary), where it develops after a period of normal sexual function. Treatment for PE includes a combination of behavioral therapies, medications, and in some cases, psychological counseling. Behavioral techniques, such as the 'stop-start' method and the 'squeeze' technique, are commonly recommended to help men gain better control over ejaculation. Pharmacological treatments include the use of selective serotonin reuptake inhibitors (SSRIs), topical anesthetics, and oral medications like dapoxetine, which is specifically approved for the treatment of PE. These treatments aim to delay ejaculation, reduce anxiety, and improve sexual satisfaction for both partners.

How Are Technological Advancements Enhancing Premature Ejaculation Treatments?

Technological advancements have significantly improved the options available for treating premature ejaculation, offering more effective and personalized approaches to managing the condition. The development of new pharmacological treatments, such as fast-acting SSRIs and combination therapies, has provided more effective and targeted solutions for men with PE. Advances in drug delivery systems, such as topical gels and sprays that contain anesthetic agents, have made it easier to apply treatments directly to the affected area, reducing sensitivity and prolonging ejaculation without systemic side effects. Additionally, the integration of digital health tools, such as mobile apps and wearable devices, has enhanced the ability of men to monitor their symptoms, track treatment progress, and access behavioral therapy resources from the comfort of their homes. These technological improvements have expanded the range of treatment options for premature ejaculation, making it easier for men to find effective and convenient solutions that fit their individual needs.

What Are the Key Applications and Benefits of Premature Ejaculation Treatments?

Premature ejaculation treatments are used by men of all ages who experience difficulties with controlling ejaculation, offering numerous benefits that improve sexual health and overall well-being. The primary application of these treatments is to delay ejaculation, allowing for longer-lasting sexual activity and increased satisfaction for both partners. Behavioral therapies, often conducted in conjunction with a therapist or through guided self-help programs, help men develop better control and reduce performance anxiety. Pharmacological treatments, such as SSRIs and topical anesthetics, provide more immediate and reliable results, making them a popular choice for men seeking quick relief from PE symptoms. In cases where psychological factors contribute to the condition, counseling and therapy can address underlying issues, improving both sexual function and emotional health. The benefits of PE treatments include improved sexual confidence, enhanced relationship satisfaction, and a better overall quality of life. By offering a range of treatment options, men can choose the approach that best suits their needs and lifestyle, leading to more successful outcomes.

What Factors Are Driving the Growth in the Premature Ejaculation Treatment Market?

The growth in the premature ejaculation treatment market is driven by several factors. The increasing awareness and recognition of PE as a common and treatable condition are significant drivers, encouraging more men to seek treatment. Technological advancements that enhance the effectiveness, convenience, and personalization of treatment options are also propelling market growth. The rising prevalence of lifestyle factors that contribute to sexual dysfunction, such as stress, anxiety, and poor health, is further boosting demand for PE treatments. Additionally, the expansion of telemedicine and online health platforms has made it easier for men to access treatment discreetly, contributing to market growth. The increasing availability of over-the-counter and prescription medications, as well as the growing acceptance of behavioral therapies, are further supporting the market. These factors, combined with the continuous innovation in sexual health treatments, are driving the sustained growth of the premature ejaculation treatment market.
 

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Selective Serotonin Reuptake Inhibitors (SSRIs) segment, which is expected to reach US$1.8 Billion by 2030 with a CAGR of a 6.9%. The Tricyclic Antidepressant segment is also set to grow at 8.3% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, which was estimated at $740.5 Million in 2023, and China, forecasted to grow at an impressive 6.9% CAGR to reach $686.5 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Premature Ejaculation Treatment Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Premature Ejaculation Treatment Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Premature Ejaculation Treatment Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Absorption Pharmaceuticals Inc., Allergan PLC, AstraZeneca PLC, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 31 Featured):

  • Absorption Pharmaceuticals Inc.
  • Allergan PLC
  • AstraZeneca PLC
  • Bayer AG
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Innovus Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Premature Ejaculation Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • Global Economic Update
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Awareness of Sexual Health and Wellness Propels Market Growth
  • Technological Advancements in Treatment Options Enhance Product Offerings
  • Growing Acceptance and Reduction of Stigma Throws the Spotlight on Treatment Solutions
  • Focus on Effective and Long-lasting Therapies Strengthens Business Case
  • Expansion of Telemedicine and Online Consultations Boosts Market Accessibility
  • Rising Demand for Non-invasive and Drug-free Treatments Sustains Market Growth
  • Increasing Adoption of Behavioral Therapy and Counseling Drives Market Dynamics
  • Growing Use of Topical Anesthetics and Oral Medications Enhances Market Prospects
  • Focus on Patient Education and Awareness Campaigns Spurs Market Demand
  • Advancements in Psychological and Pharmacological Treatments Propel Market Expansion
  • Focus on Customized and Personalized Treatment Plans Enhances Market Opportunities
  • Increasing Healthcare Expenditure and Insurance Coverage Boosts Market Prospects
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Premature Ejaculation Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 3: World 16-Year Perspective for Premature Ejaculation Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Selective Serotonin Reuptake Inhibitors (SSRIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Selective Serotonin Reuptake Inhibitors (SSRIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 6: World 16-Year Perspective for Selective Serotonin Reuptake Inhibitors (SSRIs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Tricyclic Antidepressant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Tricyclic Antidepressant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 9: World 16-Year Perspective for Tricyclic Antidepressant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Topical Anesthetic Agent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 11: World Historic Review for Topical Anesthetic Agent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 12: World 16-Year Perspective for Topical Anesthetic Agent by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Phosphodiesterase Type 5 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 14: World Historic Review for Phosphodiesterase Type 5 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 15: World 16-Year Perspective for Phosphodiesterase Type 5 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 17: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 18: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 19: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 20: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 21: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 23: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 24: World 16-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 25: World Premature Ejaculation Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Premature Ejaculation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 28: USA 16-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 29: USA Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 31: USA 16-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2014, 2024 & 2030
CANADA
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 34: Canada 16-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 37: Canada 16-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2014, 2024 & 2030
JAPAN
  • Premature Ejaculation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Japan Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 40: Japan 16-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 41: Japan Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Japan Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 43: Japan 16-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2014, 2024 & 2030
CHINA
  • Premature Ejaculation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 44: China Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 45: China Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 46: China 16-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 47: China Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 48: China Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 49: China 16-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2014, 2024 & 2030
EUROPE
  • Premature Ejaculation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Premature Ejaculation Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 52: Europe 16-Year Perspective for Premature Ejaculation Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 58: Europe 16-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2014, 2024 & 2030
FRANCE
  • Premature Ejaculation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 59: France Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 60: France Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 61: France 16-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 62: France Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 63: France Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 64: France 16-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2014, 2024 & 2030
GERMANY
  • Premature Ejaculation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 65: Germany Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Germany Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 67: Germany 16-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 68: Germany Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Germany Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 70: Germany 16-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2014, 2024 & 2030
ITALY
  • TABLE 71: Italy Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Italy Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 73: Italy 16-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 74: Italy Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Italy Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 76: Italy 16-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Premature Ejaculation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 77: UK Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 78: UK Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 79: UK 16-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 80: UK Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 81: UK Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 82: UK 16-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2014, 2024 & 2030
REST OF EUROPE
  • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Rest of Europe Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 85: Rest of Europe 16-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Rest of Europe Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 88: Rest of Europe 16-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Premature Ejaculation Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Asia-Pacific Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 91: Asia-Pacific 16-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Asia-Pacific Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 94: Asia-Pacific 16-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2014, 2024 & 2030
REST OF WORLD
  • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Rest of World Historic Review for Premature Ejaculation Treatment by Drug Class - Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 97: Rest of World 16-Year Perspective for Premature Ejaculation Treatment by Drug Class - Percentage Breakdown of Value Sales for Selective Serotonin Reuptake Inhibitors (SSRIs), Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Rest of World Historic Review for Premature Ejaculation Treatment by Route Of Administration - Oral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 100: Rest of World 16-Year Perspective for Premature Ejaculation Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral and Topical for the Years 2014, 2024 & 2030
IV. COMPETITION

Companies Mentioned

  • Absorption Pharmaceuticals Inc.
  • Allergan PLC
  • AstraZeneca PLC
  • Bayer AG
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Innovus Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.

Table Information